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Recent structural studies have outlined the mecha-
nism of protease inhibition by active site-directed
antibodies.However, themolecular basis of allosteric
inhibition by antibodies has been elusive. Here we
report the 2.35 A˚ resolution structure of the trypsin-
like serine protease hepatocyte growth factor acti-
vator (HGFA) in complex with the allosteric antibody
Ab40, a potent inhibitor of HGFA catalytic activity.
The antibody binds at the periphery of the substrate
binding cleft and imposes a conformational change
on the entire 99-loop (chymotrypsinogen numbering).
The altered conformation of the 99-loop is incompat-
ible with substrate binding due to the partial collapse
of subsite S2 and the reorganization of subsite S4.
Remarkably, a single residue deletion of Ab40 abol-
ished inhibition of HGFA activity, commensurate
with the reversal of the 99-loop conformation to its
‘‘competent’’ state. The results define an ‘‘allosteric
switch’’ mechanism as the basis of protease inhibi-
tion by an allosteric antibody.
INTRODUCTION
Allostery, aptly termed the ‘‘second secret of life,’’ is an efficient
mechanism for the modulation and regulation of protein activity
(Fenton, 2008; Monod, 1971). Conformational plasticity is a key
intrinsic property that confers on proteins the ability to be alloste-
rically modulated in order to accomplish a variety of cellular
functions (Changeux and Edelstein, 2005; del Sol et al., 2009;
Krauss, 2003). In fact, all dynamic proteins (monomeric and
multimeric) seem to have a potential for allosterism (Gunase-
karan et al., 2004). Elucidation of allosteric modulation and its
pathways of communication has received considerable attention
(Swain and Gierasch, 2006; Yu and Koshland, 2001). A classic
example of allostery is observed in hemoglobin (Perutz, 1970),
which offered the first mechanistic insights on allosteric regula-
tion. Several X-ray crystallographic studies emerged thereafter
describing the conformational changes during allosteric regula-
tion (Changeux and Edelstein, 2005; Di Cera, 2006; Pellicena
and Kuriyan, 2006; Xu et al., 1997). Allostery is also a quite
common and powerful mechanism to regulate the catalytic1614 Structure 17, 1614–1624, December 9, 2009 ª2009 Elsevier Lactivity of proteases (Hauske et al., 2008; Turk, 2006). Examples
of allosteric regulators in the serine protease family (Clan PA,
Family S1 in MEROPS nomenclature [Rawlings et al., 2008])
are the accessory PDZ domains in the HtrA protease family
(Sohn et al., 2007), calcium for many coagulation factors (Bjelke
et al., 2008), sodium for thrombin (Huntington, 2008; Wells and Di
Cera, 1992), cofactors such as tissue factor for coagulation
factor VIIa (Eigenbrot and Kirchhofer, 2002), and N-terminal
peptide insertion into the ‘‘activation pocket’’ (Friedrich et al.,
2003; Huber and Bode, 1978).
Many proteases have been implicated in human pathological
processes (Barrett et al., 1998; Egeblad and Werb, 2002;
Hooper, 2002; Luttun et al., 2000). Therefore, regulation of
proteolytic activity by allosteric inhibitors might represent a
promising alternative approach to active-site inhibitors (Peterson
and Golemis, 2004), which often suffer from inadequate speci-
ficity, because active-site topologies are generally conserved
among members of the same family (Hedstrom, 2002). Unlike
active sites, distally located allosteric sites are usually less
conserved and can be exploited to achieve specificity (Hauske
et al., 2008). Excellent examples of specific and potent allosteric
inhibitors have been described for coagulation factor VIIa and
caspases (Hardy et al., 2004; Hardy and Wells, 2009).
To exploit allosteric protease inhibition for therapeutic pur-
poses, antibodies may be the inhibitor class of choice, because
they have exquisite specificity and excellent pharmacokinetic
properties and are successfully used to treat various life-threat-
ening diseases (Adams and Weiner, 2005). In addition, nearly
half of the proteases in the human genome are extracellular
and theoretically accessible to inhibition by antibodies (Farady
et al., 2008; Wu et al., 2007). Recent structural studies on
protease inhibition by antibodies have provided the first struc-
tural insights into the underlying inhibitory mechanisms. Active
site-directed antibodies that sterically block substrate access
utilize their complementarity determining region (CDR) loops to
embrace critical protease surface loops of the substrate binding
cleft and insert one or two CDR heavy chain loops into the cleft to
occupy important substrate binding subsites (Farady et al.,
2008; Wu et al., 2007). On the other hand, despite structural
data on an allosteric antibody, the precise inhibitory mechanism
remained elusive (Wu et al., 2007).
To obtain a clear understanding of antibody-mediated allo-
steric protease inhibition, we used hepatocyte growth factor acti-
vator (HGFA) (Kataoka et al., 2003; Miyazawa et al., 1993) as
a model system. HGFA is a prototypic extracellular trypsin-liketd All rights reserved
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Allosteric Inhibition of a Protease by AntibodiesTable 1. Antibody Binding to HGFA
HGFA HGFA-KQLR Complex
kon (3 10
5 M1 s-1) koff (3 10
4 s1) KD (nM) kon (3 10
5 M1 s1) koff (3 10
4 s1) KD (nM)
Ab39 5.2 ± 0.5 53.0 ± 2.0 10.3 ± 1.3 n.d. n.d. n.d.
Ab40 10.8 ± 0.46 1.75 ± 0.08 0.16 ± 0.01 3.2 ± 0.14 4.3 ± 0.13 1.35 ± 0.1
Ab40.DTrpa — — 150 ± 9.1 — — 161 ± 7.6
Throughout the manuscript, we designated the IgG form of antibody with prefix Ab and the Fab form with prefix Fab. The amino acids of Fab are
indicated with a letter-code followed by the residue number, followed by H for heavy chain and L for light chain. n.d., not determined.
a The KD values were determined using steady-state affinity measurements.serine protease with restricted substrate specificity. Only two
macromolecular substrates, pro-hepatocyte growth factor (pro-
HGF) (Shimomura et al., 1995) and pro-macrophage stimulating
protein (pro-MSP) (Kawaguchi et al., 2009), are known to be
processed by HGFA, exemplifying the enzyme’s highly restricted
substrate specificity. HGFA is inhibited by the Kunitz-type
inhibitor HGFA inhibitor 1, which utilizes the N-terminal Kunitz
domain 1 (KD1) to inhibit HGFA by a canonical inhibition mecha-
nism (Shia et al., 2005). HGFA effects tissue regeneration and
promotes cancer growth via pro-HGF processing and ensuing
activation of the HGF/Met signaling pathway (Parr and Jiang,
2001).
Here we describe the generation of a high-affinity anti-HGFA
antibody and use enzyme assays and three X-ray structures to
show its inhibitory activity is allosteric in nature. Furthermore,
the structural results reveal a distinct conformational change
transmitted from the antibody epitope to the enzyme substrate
binding cleft that can be relieved by a single amino acid deletion
in the antibody. In this way, both the origin and the final readout
of an allosteric influence are known at the level of single amino
acids, along with a complete view of the transmission along all
the intervening residues.
RESULTS
Generation of Anti-HGFA Phage Antibody
Ab39 was identified by screening of a synthetic F(ab’)2 phage
display library (Wu et al., 2007). Ab39 was subsequently
affinity-maturated as described in Supplemental Data (availableStructure 17, 1614–1online). The improvement in binding affinity as measured by
surface plasmon resonance experiments was 64-fold (Table 1),
due to four changes in the sequence of CDR-L3 (Figure 1). The
binding specificities of both Ab39 and Ab40 were assessed
by using an enzyme-linked immunosorbent assay (ELISA) to
measure binding to structurally related proteases, including the
closest homologs factor XIIa and urokinase (Miyazawa et al.,
1993). The results demonstrated a complete lack of binding to
factor XIIa, urokinase, and matriptase, suggesting good speci-
ficity (see Figure S1A).
Enzyme Kinetics and Effects of Active-Site Occupancy
on Ab40 Binding
Ab40 inhibited the cleavage of pro-HGF into the a/b-heterodimer
mediated by HGFA (Figure 2A) with a potency that agreed with its
binding affinity (Table 1). The inhibitory effects of Ab39 and Ab40
were also assessed in enzymatic assays using the synthetic
para-nitroanilide substrate Chromogenix S-2266 (H-D-Val-Leu-
Arg-pNA). The enzymatic activity of HGFA was only partially
inhibited by Ab40 (Figure 2B), with a maximum inhibition of about
60% under the chosen experimental conditions. Eadie–Hofstee
plots demonstrated that the inhibition mechanism was compet-
itive because Ab40 (and Ab39) increased the Kappm but not V
app
max
values (Figure 2C; Figure S1B). In accordance with partial inhibi-
tion, the slopes (Kappm ) approached a finite limit at high Ab40
concentration. Similar results were obtained with the parental
Ab39 (Figure S1B), demonstrating that Ab39 and Ab40 were
partial competitive inhibitors of HGFA. To analyze the influence
of active site occupancy on the antibody binding, we measuredFigure 1. CDR Sequences of Anti-HGFA Antibodies
The residues are numbered according to the Kabat numbering system (Kabat et al., 1991). The sequence variations between Ab39 and Ab40 are shaded. A single
residue deletion (Trp96H) of Fab40 is highlighted in bold.624, December 9, 2009 ª2009 Elsevier Ltd All rights reserved 1615
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Allosteric Inhibition of a Protease by AntibodiesFigure 2. Inhibition of HGFA Enzymatic Activity by Ab40
(A) Cleavage of 125I-pro-HGF by HGFA in presence of 3-fold serial dilutions of Ab40. The cleavage products HGF a and b chain were analyzed by SDS-PAGE
(reducing conditions) and subsequent X-ray film exposure.
(B) Partial inhibition of chromogenic substrate, S-2266 hydrolysis (expressed as HGFA fractional activity ni /no) by Ab40 and lack of inhibition by Ab40.DTrp. Error
bars represent standard deviation (SD).
(C) Eadie-Hofstee plot of HGFA inhibition by Ab40 (1–0.004 mM in 3-fold dilution steps; filled diamonds = ‘‘no antibody’’ control) shows competitive inhibition
(Vmax = 0.99 mM pNA/min and Km = 0.23 mM for control; V
app
max = 0.99 mM pNA/min and K
app
m = 0.82 mM for 1 mM Ab40).antibody binding to HGFA in the presence of small-molecule and
macromolecular inhibitors. Benzamidine, which only binds in the
S1 pocket of trypsin-like serine proteases, did not interfere with
binding of Ab40 to HGFA (data not shown). A peptidic inhibitor
matching the pro-HGF cleavage sequence coupled to a war-
head group (Ac-KQLR-cmk) was used to covalently modify
HGFA in the active site, where it occupied the S4-S1 subsites.
Surface plasmon resonance studies with HGFA-KQLR complex
showed that the irreversibly bound peptidic inhibitor interfered
with the binding of Ab40 (Figures 3A and 3B). An 8-fold decrease
in affinity of Ab40 binding to HGFA-KQLR complex compared
with HGFA was observed (Table 1). The Kunitz domain inhibitor
KD1, which interacts with the extended active-site region (Shia
et al., 2005), also interferes with Ab40 binding in surface plasmon
resonance experiments (Figure 3C). In agreement, a competition
ELISA showed moderate inhibition of KD1 binding to HGFA by
Ab40 (Figure 3D). In summary, binding of Ab40 to HGFA was
influenced by inhibitor occupancy at extended subsites,
including S2-S4 but not S1.
Structure of the HGFA/Fab40 Complex Reveals
the ‘‘Allosteric Switch’’
The 2.35 A˚ resolution structure of the HGFA/Fab40 complex
shows that Fab40 uses all six CDR loops to bind to a flat epitope
at the periphery of the substrate binding cleft, encompassing the
60-loop and 99-loop (Figures 4A and 4B). The conformation of the
catalytic triad (His-57, Asp-102, and Ser-195) has no significant
changes compared with other known structures of HGFA
(Figure 4B) and the substrate subsites S1-S4 are unoccupied
(Figure 5A). The closest atom of Fab40 is > 15 A˚ from the active
site Ser195 residue, indicating an allosteric mode of inhibition.
The key feature of the HGFA/Fab40 complex is a large conforma-
tional change in the 99-loop (Figure 4B and Figure S2, illustrating
the quality of the electron density map). No other significant
changes in the HGFA structure are observed suggesting that
this is the reason for antibody induced inhibition. The allosteric
switch, embodied in the conformation of the 99-loop, is evident
from the comparison of the HGFA/Fab40 structure with other1616 Structure 17, 1614–1624, December 9, 2009 ª2009 Elsevier Ltstructures of HGFA (Shia et al., 2005; Wu et al., 2007), in which
the 99-loop is in a ‘‘competent’’ conformation (catalytically active
form of HGFA). The Phe97 of the 99-loop in the new conformation
(‘‘noncompetent’’ conformation, catalytically inactive form of
HGFA) is buried in a hydrophobic groove formed at the interface
of light chain (Tyr49L, Ser50L, and Phe53L) and heavy chain
(Trp98H and Pro99H) of Fab40 (Figure 4C). The epitope is
centered on Leu-93 of the protruding 99-loop (Figures 5A and
5B), which is sandwiched in a cleft between the CDR loops L3
and H3. The 99-loop and 60-loop are involved in intimate contacts
mostly withheavy-chainCDR residues. The heavyand light chains
contribute 65% and 35% of buried surface area to the complex,
respectively (Figure 5C). The total solvent-accessible surface
area of HGFA buried upon Fab40 binding is1030 A˚2. Altogether,
17 hydrogen bonds and one electrostatic interaction (Asp241-
Lys64H) are formed between HGFA and Fab40 (Table S1). Several
hydrophobic residues like Trp95H, Trp96H, Trp98H, and Tyr33H,
Tyr52H, Tyr58H bind into small pockets at the back side of the
60- and 99-loops (Figure 4C). The Fab40 epitope on HGFA has
significant overlap with a region corresponding to exosite II in
thrombin, an electropositive region that interacts with thrombin
regulators (Figure 5B). However, unlike exosite II interactions in
coagulation proteases, which are primarily electrostatic in nature
(Bock et al., 2007), the binding of Fab40 to HGFA involves mainly
hydrogen bonding and van der Waals interactions.
Flipping the Allosteric Switch: Engineering Ab40
to Remove the Allosteric Inhibitory Activity
The CDR-H3 loop of Fab40 contains 3 tryptophan residues
(Trp95H, Trp96H, and Trp98H) that form the core of the paratope
(Figure 5C). Trp96H is central to the observed conformational
change in the 99-loop, by docking its large indole side chain
in a deep hydrophobic pocket formed by Ala56, Pro90, Tyr88,
Val96, Val104, and Ile106 of HGFA (Figure 6A). A small shift in
the main-chain as well as the side-chain conformation of Val96
is transmitted through the rest of the 99-loop residues (Val96-
Asp100), ultimately leading to > 1 A˚ root-mean-square deviation
(rmsd) shift in Ca (99-loop) (Figures 6C and 6D). To investigate thed All rights reserved
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Allosteric Inhibition of a Protease by AntibodiesFigure 3. Effects of Active Site Inhibitors on Antibody Binding to HGFA
(A, B, E, F) Surface plasmon resonance (BIAcore) measurements of binding to immobilized antibodies, Ab40 (A, B) or Ab40.DTrp (E, F), after coinjection of HGFA
(A and E) or HGFA-KQLR (B and F) complex.
(C) Competition binding (BIAcore) of HGFA to immobilized Ab40 in presence of different concentrations of KD1.
(D) Competition binding ELISA measuring binding of HGFA to biotinylated KD1 in the presence of increasing antibody concentrations. Error bars represent SD.role of Trp96H in the conformational change and the associated
allosteric inhibitory activity, we deleted this residue (Fab40.DTrp)
to shorten the CDR-H3 loop (Figure 1). The complex of HGFA
with Fab40.DTrp was crystallized as described for the wild-
type antibody.
The overall structure of HGFA/Fab40.DTrp (2.90 A˚) is very
similar to that of HGFA/Fab40. The changes are very minimal
and confined to residues Ala97H and Trp98H in the CDR-H3
loop (Figures 6E and 6F). The side chain of Tyr33H flips around
its c1 torsion angle and partly fills the deep hydrophobic pocket
that was occupied by Trp96H in the HGFA/Fab40 structure
(Figure 6B). The size of this hydrophobic pocket is now reduced
due to the movement of residues lining this pocket, principally
Ser60, Pro90, and Tyr94 of HGFA. Remarkably the 99-loop
reverted to the competent state, as observed in other structures
of HGFA (Figures 6E and 6F). Ab40.DTrp was no longer an
inhibitor of HGFA as determined by enzymatic assays (Fig-
ure 2B). It was striking that such a subtle change was enough
to remove the inhibitory activity while retaining binding, albeit
with much reduced affinity (Table 1). Moreover, unlike Ab40,
presence of the KQLR inhibitor in the HGFA active site did not
affect Ab40.DTrp binding as indicated by the similar KD valuesStructure 17, 1614–1for either HGFA or HGFA-KQLR complex (Figures 3E and 3F).
Thus, the data support our hypothesis that the mechanism of
allosteric inhibitory activity by Ab40 is primarily driven by a signif-
icant change of the 99-loop conformation.
Structural Determinants for the Allosteric Mechanism
of Inhibition
The 99-loop of HGFA is a critical substrate specificity determi-
nant by contributing to interactions with substrate residues P2
and P4. Therefore, to obtain a detailed understanding on how
the Ab40-induced movement of the 99-loop impacted these
substrate subsite interactions, we attempted to determine the
structure of the HGFA-KQLR complex. The KQLR sequence
corresponds to the P4-P1 residues of the natural HGFA
substrate pro-HGF. Unfortunately, these attempts were not
successful in producing crystals of sufficient diffraction quality
despite several attempts to optimize the crystallization condi-
tions. As an alternative approach, we then focused our attention
on solving the structure of HGFA-KQLR in complex Fab40.DTrp,
which readily crystallized.
The electron density for peptidic inhibitor, Ac-KQLR-cmk was
unambiguous in this 2.70 A˚ resolution structure. The peptidic624, December 9, 2009 ª2009 Elsevier Ltd All rights reserved 1617
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Allosteric Inhibition of a Protease by AntibodiesFigure 4. Structure of HGFA/Fab40 Complex
(A) Surface representation with secondary structure highlighted for the complex between HGFA (beige) and Fab40 (light chain in blue, heavy chain in teal). The
catalytic triad (His57-Asp102-Ser195) residues are indicated in yellow and the 99-loop is highlighted in red.
(B) Superposition of HGFA/Fab40 (beige) structure with HGFA/Fab75 (Wu et al., 2007) (green) showing no significant changes in the conformation of HGFA except
for changes in the 99-loop (red).
(C) A close view of interactions of CDR-loops (L1-3, H1-3) of Fab40 with HGFA (surface representation). Critical residues involved in the interface interactions are
highlighted and the 99-loop is indicated in red. Apart from several hydrogen bonds (red dotted line), a single salt bridge between Asp241 of HGFA and Lys64H of
Fab40 is observed.inhibitor aligned in the active site groove in a twisted antiparallel
conformation forming the characteristic inter-main-chain
hydrogen bonds between P1-Arg and Ser214 and between
P3-Gln and Gly216 (Figure S3). The inhibitor was covalently
linked to the catalytic Ser195 and His57 and the mode of binding
at S4-S1 subsites are very similar to those observed in the
complex of KQLR with hepsin, another S1A protease family
member (Herter et al., 2005). A salt bridge interaction pairs the
P1-Arg of the peptidic inhibitor with Asp189 in the S1 subsite.
There appears to be a strong preference for a leucine at the P2
position, because the S2 subsite is a small hydrophobic pocket
formed by residues Pro99a, Ser99, Trp215 and His57. The P2-1618 Structure 17, 1614–1624, December 9, 2009 ª2009 Elsevier LtLeu side chain tightly packs against the Pro99a, suggesting
that minor changes in the conformation of Pro99a could have
a major influence on P2 specificity (Figure 7A). Thus the speci-
ficity at the S2 subsite for HGFA appears to be a distinguishing
feature, as is the case for many coagulation proteases. Selec-
tivity for the P3 residue is poor in nearly all S1 peptidases
because the enzyme–substrate interaction is limited due to
solvent exposure of the P3 side chain. The P3-Glu points
outward toward the solvent exposed region of the active site.
Unlike most S1 peptidases, which possess poor selectivity for
a P4 residue, in HGFA a hydrogen bond with Ser99 stabilizes
the P4-Lys (Figure 7A). Additionally, hydrophobic stabilizationFigure 5. HGFA/Fab40 Epitope and Paratope
HGFA/Fab40 epitope and paratope, with HGFA (beige) and Fab40 (light chain in blue, heavy chain in teal).
(A) Epitope of the Fab40 contact region (orange, 4 A˚ cutoff) on HGFA (beige).
The catalytic triad and the substrate binding subsites S1-S4 are indicated.
(B) A different view of the Fab40 contact region on HGFA, which has a partial overlap with a region corresponding to exosite-II in thrombin (green).
(C) The HGFA contact region on Fab40 (heavy chain contacts in brown, light chain contacts in purple, 4 A˚ cutoff). The heavy chain is involved in intimate contacts
with HGFA and contributes to two-thirds of the total accessible surface area buried on HGFA upon Fab40 binding.d All rights reserved
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Allosteric Inhibition of a Protease by AntibodiesFigure 6. The Three Structural Snapshots of the 99-Loop of HGFA
(A) The allosteric switch in the conformation of the 99-loop leads to the formation
of a deep hydrophobic pocket (colored in olive, residues Ala56, Pro90, Tyr88,
Val96, Val104, and Ile106 of HGFA) allowing the binding of Trp96H of Fab40.
(B) Size of the hydrophobic pocket (colored in olive) in HGFA/Fab40.DTrp is
severely restricted due to movement of Val96 and other residues lining this
pocket.
(C) The competent state conformation of the 99-loop of HGFA as found in
other known structures (Shia et al., 2005; Wu et al., 2007).
(D) Superposition of the 99-loop of HGFA (green) and HGFA/Fab40 (red)
complex. Conformation transition of the 99-loop upon Fab40 binding, main
chain of the 99-loop residues are shifted by > 1 A˚, while the side chain confor-
mations are dislodged by > 2.0 A˚. The CDR-H3 loop of Fab40 is highlighted in
stick representation (teal).
(E) Superposition of the 99-loop of HGFA/Fab40.DTrp with the 99-loop of
HGFA. The conformation of the 99-loop (mustard) reverts almost back to the
competent state in the Fab40.DTrp/HGFA complex structure. The CDR-H3
loop of Fab40. DTrp is highlighted in stick representation (orange).Structure 17, 1614–1to the side chain of P4-Lys is offered by Trp215 of HGFA. The
carbonyl oxygen from the N-terminal acetyl group is interacting
with Asp217 of HGFA through a hydrogen bond.
The structure of the protease domain of HGFA in HGFA-KQLR/
Fab40.DTrp complex is very similar to HGFA/Fab40.DTrp
complex with rmsd (for all atoms) of 0.39 A˚ (Figure S4). The
conformation of the 99-loop in HGFA-KQLR/Fab40.DTrp struc-
ture is in the competent state as found in HGFA/Fab40.DTrp
and other structures of HGFA. Thus, the HGFA-KQLR/
Fab40.DTrp is a good alternative in the absence of a HGFA-
KQLR structure, to define the substrate binding subsites in
HGFA. Superposition of HGFA/Fab40 structure with HGFA-
KQLR/Fab40.DTrp revealed a plausible cause for the allosteric
inhibition. The movement of the 99-loop leads to a partial collapse
of the subsite S2 and the reorganization of subsite S4, perturbing
the interactions with substrate residues P2 and P4. First, the
movement of the 99-loop residues Pro99a and Ser99, which
are part of the S2 pocket, positions them too close to the
P2-Leu (Figure 7B), creating a steric clash. Second, the reposi-
tioned hydroxyl side chain of the S4 residue Ser99 can no longer
form the hydrogen bond with P4-Lys (Figures 7A and 7B) and is
positioned too close to P2-Leu. Furthermore, the movement of
the S2 pocket residue Pro99a also plays a key role in defining
the allosteric nature of the inhibition of KD1 binding to HGFA
by Ab40. Superposition of HGFA/Fab40 and HGFA/KD1 (Shia
et al., 2005) complexes showed that there was no overlap
between the KD1- and Fab40 epitopes (Figure S5). A model of
HGFA/Fab40/KD1 predicts a possibility of Pro99a to sterically
clash with Cys38 and Leu39 of KD1 at the S2 subsite.
DISCUSSION
Allosteric regulation of an enzyme, by definition, involves an
altered catalytic activity originating from a remote effector inter-
action site (Tsai et al., 2009). A variety of effectors including
binding of small molecules or macromolecules, phosphoryla-
tion, etc., result in a signal, which may either activate or inhibit
a particular function of the protein (Swain and Gierasch, 2006).
Very few such systems are understood beyond knowledge of
the effector interaction site and the site of altered activity (del
Sol et al., 2009). The exact route by which amino acids transmit
the allosteric effect is, in general, very poorly known. Recent
studies have provided new insight into the structural basis of
protease inhibition by antibodies that target the enzyme active
site (Farady et al., 2008; Wu et al., 2007). In contrast, the exact
molecular mechanisms by which allosteric antibodies interfere
with enzyme catalysis remain elusive. The findings presented
herein, derived from comprehensive structural and kinetic
studies, now provide a detailed view of how an allosteric anti-
body inhibits protease catalysis. Enzyme kinetic analysis
demonstrates that the phage display-derived Ab40 is a compet-
itive inhibitor of HGFA. Yet, Ab40 did not inhibit by ‘‘classical’’
steric hindrance, because it bound to an epitope distant from
the active site, thus defining a competitive inhibition mechanism
that is allosteric in nature. Most importantly, the structure of
(F) Superposition of the 99-loop of HGFA/Fab40.DTrp (mustard) with the 99-
loop of HGFA/Fab40 (red), indicating minor changes in CDR-H3 loop upon
deletion of Trp96H of Fab40 (dotted circle).624, December 9, 2009 ª2009 Elsevier Ltd All rights reserved 1619
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Allosteric Inhibition of a Protease by AntibodiesFab40/HGFA complex revealed the underlying conformational
changes, i.e., the movement of the 99-loop, thereby establishing
the structural basis for a functional conduit between epitope and
active site.
The observed 99-loop flexibility is unusual in the family of
trypsin-like serine proteases, because it is not a part of the
Figure 7. The Allosteric Mechanism
(A) Stereo view of the peptidic inhibitor Ac-KQLR-cmk (sticks embedded in
CPK sphere representation in green) is covalently linked to active site Ser195
and His57 of HGFA in the HGFA-KQLR/Fab40.DTrp complex. The P2-Leu
packs tightly against Pro99a of the 99-loop (sticks embedded in dots represen-
tation in beige) and a hydrogen bond with Ser99 stabilizes the P4-Lys.
(B) Stereo view of a model of HGFA-KQLR/Fab40 obtained by from the super-
position of HGFA/Fab40 structure with HGFA-KQLR/Fab40.DTrp shows that
the allosteric inhibition is due to the steric clash between Pro99a and Ser99
with P2-Leu (sticks [red] embedded in dots representation in white).
(C) Stereo view of the superposition of HGFA-KQLR/Fab40.DTrp with the
model of HGFA-KQLR/Fab40 highlighting the critical conformational changes
and disruption of hydrogen bond between Ser99 of HGFA and P4-Lys of the
inhibitor.1620 Structure 17, 1614–1624, December 9, 2009 ª2009 Elsevier Ltdso-called activation domain, which comprises several intrinsi-
cally mobile surface loops (Huber and Bode, 1978). A known
example of conformational flexibility in the 99-loop is observed
in the serine protease prostasin (Spraggon et al., 2009).
Ab40 binding was not accompanied by any major structural
changes other than the 99-loop movement, strongly indicating
that this was the cause for enzyme inhibition. To test this hypoth-
esis, we removed one of the key interactions at the Ab40/HGFA
interface, i.e., the hydrophobic contact between Trp96H and
Val96 of HGFA. The structure of the generated Trp96H-deletion
mutant Ab40.DTrp in complex with HGFA showed that the
99-loop had flipped back to the functionally competent state,
consistent with assay results showing that the Ab40.DTrp/
HGFA complex was enzymatically active. Therefore, the 99-loop
movement could be considered as an allosteric switch regulating
enzyme activity: the allosteric switch is turned ON upon Ab40
binding locking the 99-loop in the noncompetent conformation,
whereas antibody removal or binding of the Ab40.DTrp mutant
turns the allosteric switch OFF, allowing the 99-loop to adopt
the competent conformation. The question arose as to exactly
how the noncompetent 99-loop conformation interferes with
the catalytic machinery. That is, which amino acids are changed
when Ab40 binds, and why do those changes alter enzyme
activity? The 99-loop does not contribute to the formation of
the S1 specificity pocket and binding experiments confirmed
that S1-P1 interactions were not affected by Ab40 binding.
However, the ‘‘front’’ side of the 99-loop in respect to the Ab40
epitope participates in shaping important substrate subsites,
and this is the region where obstructions likely arose. The struc-
ture of HGFA with the irreversibly bound KQLR peptide provided
a plausible answer. The KQLR peptide constitutes the P4-P1
sequence of the natural substrate pro-HGF and also contains
the P2-P1 residues, i.e., LR, of the synthetic pNA substrate
S-2266 used in our enzyme assays.
Structural analysis showed that the noncompetent conforma-
tion of the 99-loop obstructed substrate access to S2 and S4
subsites, due to a steric clash between the P2-Leu and the S2
subsite (Pro99a and Ser99) and the loss of stabilizing interac-
tions between P4-Lys and the S4 subsite. The hydroxyl side
chain of Ser99 was found to adopt two different conformations,
thus acting as a key specificity determinant at the S2 subsite.
This observation is analogous to the conformational changes
observed in Tyr99 of coagulation factor IXa (Hopfner et al.,
1999). In the competent conformation the hydrophobic S2
pocket is ideally shaped to recognize Leu as a P2 residue,
consistent with the presence of P2-Leu in the natural substrates
pro-HGF and pro-MSP, as well as the synthetic S-2266
substrate. Therefore, the partial collapse of the S2 subsite by
Ab40 binding may have sufficed to cause inhibition of enzyme
catalysis toward both macromolecular and synthetic substrates.
A caveat associated with this structural interpretation is our use
of the HGFA-KQLR/Fab40.DTrp structure as a surrogate for that
of HGFA-KQLR, which we failed to crystallize. However, the
99-loop in the HGFA-KQLR/Fab40.DTrp structure adopts the
competent conformation and, therefore, we take this structure
as to provide a very good approximation of the S4-S1 interac-
tions with substrate. This view is supported by the observation
that the conformation of the KQLR peptide is virtually identical
with that in the related KQLR-hepsin complex (Herter et al.,All rights reserved
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contacts on the interpretation of our results. The catalytic triad
(H57-D102-S195) is not involved in crystal contacts in any of
the three structures. Additionally, the 99-loop is not involved in
crystal contacts in the structure of HGFA/Fab40 or HGFA-
KQLR/Fab40.DTrp. However, the 99-loop is stabilized by
a symmetry-related molecule in the case of HGFA/Fab40.DTrp
(both molecules in the asymmetric unit). Because the conforma-
tion of the 99-loop in HGFA-KQLR/Fab40.DTrp is similar as in
HGFA/Fab40.DTrp, we considered the impact from crystal
contacts negligible.
The switch of the 99-loop can be considered as a mobile
conduit that connects the inhibitor (i.e., Ab40) binding site with
the substrate binding site. Such a view would also provide a suit-
able framework for understanding the competitive inhibition
mode determined in enzymatic assays. Both inhibitor and
substrate can apply forces on the 99-loop, albeit from opposite
directions, resulting in 99-loop conformations that are subop-
timal with either substrate binding (noncompetent state) or
inhibitor binding (competent state). Structural models indicate
that steric clashes occur in both situations, i.e., between the
99-loop and P2-Leu of substrate in the noncompetent state
(Figure 7C) and between the 99-loop and Trp96H, Ala97H, and
Trp98H in CDR-H3 of Fab40 in the competent state (Figure S6).
Several models of competitive inhibition have been proposed
based on classical enzyme kinetics, among them allosteric
models, as illustrated by Segel (1993). The elucidated allosteric
mechanism is a refinement of the model-5 by Segel, because it
provides the structural basis of the molecular linkage between
inhibitor binding site and active site. The model in Figure 8 shows
the catalytically competent and inhibited states of enzyme in an
equilibrium favoring the competent state. In this model, the
binding of Ab40 to the transient noncompetent state (allosteric
Figure 8. A Cartoon Model Illustrating the
Allosteric Mechanism of Inhibition
In the functionally active state, binding subsites
are accessible to substrates and the allosteric
switch is in the OFF state. Fab40 preferentially
samples one of the transiently formed conforma-
tions and shifts the equilibrium away from the
functionally active state, thus driving the major
population of enzyme molecules from the allo-
steric switch OFF state to the ON state. In
contrast, Fab40.DTrp, which does not inhibit
enzyme activity, might merely bind to the enzyme,
without driving a change in state.
site*, Figure 8) simply shifts the equilib-
rium away from the functionally active
state, thus driving the major population
of enzyme molecules from the allosteric
switch OFF state to the ON state. The
model also accounts for the competitive
nature of HGFA inhibition, in that an
increase of substrate concentration will
shift the equilibrium to the left, i.e., to
the competent state of HGFA allowing
catalysis to proceed. The mutated
Ab40.DTrp does not impede catalysis, because it only binds to
the competent state in which the allosteric switch is turned
OFF. This interpretation is consistent with the generally accepted
view of allostery in that effector binding leads to a shift in the
ensemble of protein conformations, thus altering the relative
populations of particular states. Ab40 binding to HGFA effec-
tively resulted in a shift/redistribution from the competent to
a noncompetent state and thus to a functionally impaired
enzyme. Extending this view to Ab40.DTrp, it can also be
regarded as allosteric effector, which imposes only small or
negligible effects on the binding site, thereby sampling the
competent enzyme conformation.
The allosteric switch is a relatively simple allosteric mecha-
nism. It involves only one mobile surface loop, which directly
links the allosteric effector binding site with the active site. It
contrasts with other more complex and less understood allo-
steric mechanisms, such as cofactor-induced enzyme activation
(Olsen and Persson, 2008) or PDZ-domain-mediated inhibition/
activation of HtrA family members (Sohn et al., 2007), where
effector binding is associated with multiple short- and long-
range conformational changes. Nevertheless, despite its relative
simplicity, it may replicate a naturally occurring allosteric regula-
tion mechanism of HGFA activity by yet unknown effector mole-
cules. In particular, the Ab40 binding site significantly overlaps
with the exosite II of thrombin and the corresponding region of
coagulation factors IX and X, which are docking sites for various
allosteric effectors, including heparin. However, the correspond-
ing region of HGFA appears ill-suited to bind heparin, because
the prominent cluster of Arg and Lys residues that mediate
exosite-heparin interactions in coagulation factors is minimally
represented in HGFA.
Another aspect of our study is the potential usefulness of
the anti-HGFA antibody to experimentally address the roles ofStructure 17, 1614–1624, December 9, 2009 ª2009 Elsevier Ltd All rights reserved 1621
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that the ability of HGFA to efficiently process pro-HGF and
consequently stimulate the HGF/Met signaling pathway may
contribute to cancer growth (Kataoka et al., 2003). Ab40 binds
to and blocks mouse HGFA equally well as human HGFA (data
not shown), making it an ideal reagent for further investigation
of HGFA function in mouse tumor models.
Research on allosteric inhibitors have been actively pursued
for kinases (Vajpai et al., 2008) and GPCRs (Raddatz et al.,
2007), among others. It is interesting to note that the mechanism
of allosteric inhibition by Ab40 is similar to some of the other
known allosteric small-molecule inhibitors; in either case, the
allosteric inhibitor acts by restricting the conformational flexibility
in the enzyme active site (Goodey and Benkovic, 2008; Lee and
Craik, 2009). Allosteric anti-protease antibodies may have great
therapeutic potential, because they are potent and highly specific
and are safeguarded from any inadvertent processing by their
target protease. However, their use as therapeutic agents is
currently limited to extracellular proteases, whereas intracellular
proteases are primarily targeted by orthosteric small-molecule
inhibitors. In this respect, our findings may suggest new
approaches to identify allosteric ‘‘hot spots’’ that might be
amenable to structure-based design of allosterically acting
peptidic or small-molecule inhibitor (Hardy and Wells, 2004).
Specifically, the herein described interaction of Trp96H with
a large hydrophobic pocket (hot spot) is critical in stabilizing the
noncompetent 99-loop conformation, yet the existence of this
pocket could not have been predicted from other HGFA struc-
tures. Thus, large-scale screening of Fab phage display libraries
in conjunction with Fab/protease structure determination may
identify promising allosteric hot spots. Such an approach should
further benefit from the intrinsic property of Fabs to facilitate
crystallization of proteins (Tereshko et al., 2008).
EXPERIMENTAL PROCEDURES
Antibody Phage Display
Synthetic antibody libraries displayed bivalent Fab fragments on M13 phage
and the diversity was generated by use of oligo-directed mutagenesis in three
CDRs of the heavy chain. The details of the Fab libraries were described previ-
ously (Lee et al., 2004a, 2004b). Nunc 96-well Maxisorp immunoplates were
coated overnight at 4C with HGFA (10 mg/ml) and then blocked for 1 hr at
room temperature with phage blocking buffer PBST (phosphate-buffered
saline [PBS], 1% [w/v] bovine serum albumin, 0.05% [v/v] Tween 20). The anti-
body phage libraries were added to the HGFA-coated plates and incubated
overnight at room temperature. The plates were washed with PBT (PBS,
0.05% [v/v] Tween-20) buffer and bound phage were eluted with 50 mM HCl
and 500 mM NaCl for 30 min and neutralized with an equal volume of 1 M
Tris-HCl (pH 7.5). Recovered phage was amplified in E. coli XL-1 blue cells.
During subsequent selection rounds, incubation of antibody phage with the
antigen-coated plates was reduced to 2–3 hr and the stringency of plate
washing was gradually increased.
Antibody Reformatting and Determination of Binding
Constants to HGFA
Anti-HGFA Fabs were reformatted into human IgG1 by cloning the VL and VH
regions of individual clones into LPG3 and LPG4 vector, respectively (Liang
et al., 2007). The full-length antibodies were transiently expressed in chinese
hamster ovary cells and purified on a protein-A column. To determine binding
affinities of the reformatted anti-HGFA antibodies, surface plasmon resonance
measurements on a BIAcore-3000 instrument (GE Health Care, NJ) were per-
formed. Rabbit anti-human IgG were chemically immobilized (amine coupling)1622 Structure 17, 1614–1624, December 9, 2009 ª2009 Elsevier Lon CM5 biosensor chips and the anti-HGFA antibodies were captured to give
approximately 250 response units (RU). For kinetics measurements, 2-fold
serial dilutions of HGFA or active-site-blocked HGFA (0.9 nM to 250 nM)
were injected in PBT buffer at 25C with a flow rate of 30 ml/min. HGFA-
KQLR was produced by incubating HGFA with 2-fold molar excess of
Ac-KQLR-cmk for 2 hr at room temperature, followed by size exclusion chro-
matography to remove nonincorporated Ac-KQLR-cmk. Association rates
(kon) and dissociation rates (koff) were obtained by using a simple one-to-one
Langmuir binding model (BIA-Evaluation) and the equilibrium dissociation
constants (KD) were calculated (koff/kon). Longer injection (5 min) of 2-fold serial
dilution of HGFA or HGFA-KQLR (1.5 nM to 3000 nM) over captured antibody
(Ab40.DTrp) sensor chip was implemented to achieve maximal binding (Rmax)
and reach the steady state. The values of Req (20%–80% of Rmax) were calcu-
lated and plotted individually against C (concentration of HGFA or HGFA-
KQLR) using BIA-Evaluation to determine KD at the steady-state analysis.
HGFA Purification, Enzyme Kinetic Assays,
and Competition ELISA
HGFA (Val373 - Ser655) was produced by use of a baculovirus and insect cell
expression system and purified on a Ni-NTA-agarose column, followed by size
exclusion chromatography as described previously (Kirchhofer et al., 2003).
Pro-HGF activation assays with active-site-titrated HGFA were carried out
essentially as described elsewhere (Kirchhofer et al., 2003) using serial
dilutions of antibody incubated with 1 nM HGFA and 25 mg/ml 125I-pro-HGF.
For chromogenic substrate assays with Chromogenix S-2266 (H-D-Valyl-
L-leucyl-L-arginine-para-nitroanilide) (Diapharma, Westchester, OH), 5 nM
HGFA was incubated for 40 min in 96-well plates with increasing concentra-
tions of antibodies in TNCT buffer (20 mM Tris [pH 8.0], 150 mM NaCl, 5 mM
CaCl2, 0.01%-Triton X-100). After addition of S-2266 (0.24 mM Km) the linear
rates of the increase in absorbance at 405 nm were measured on a kinetic
microplate reader (Spectramax-M5, Molecular devices, Sunnyvale, CA).
Enzyme kinetic measurements for Ab39 and Ab40 were carried out with
3 nM HGFA incubated with various antibody concentration (1–0.004 mM in
3-fold dilutions) in TNCT buffer for 40 min. Various concentrations of Chromo-
genix S-2266 were added and the linear rates of absorbance increase at 405
nm were measured. Eadie-Hofstee plots of the data obtained (v versus v/[S])
were indicative of a competitive inhibition mechanism. Competition ELISA
experiments were performed to evaluate effect of Ab40 on KD1 binding to
HGFA. A 96-well Maxisorp plate coated with HGFA (1 mg/ml) was incubated
with increasing concentrations of Ab40 in PBST buffer for 2 hr, followed by
addition of 1 nM biotinylated KD1 for 15 min. Biotinylated KD1 that was bound
to HGFA was detected by streptavidin-HRP conjugates.
Crystallography
Fab40 and Fab40.DTrp were expressed in E. coli and purified by using protein-
G sepharose followed by cation exchange chromatography. Complexes
between (a) HGFA and Fab40 (b) HGFA and Fab40.DTrp or (c) HGFA-KQLR
and Fab40.DTrp were formed by mixing in a 1:2 molar ratio and purified by
size exclusion chromatography (Superdex 200). The complexes were concen-
trated to 10 mg/ml in 10 mM HEPES (pH 7.2), 150 mM NaCl. HGFA/Fab40
and HGFA-KQLR/Fab40.DTrp complexes yielded crystals under 14% PEG
10,000, 100 mM HEPES (pH 7.2), whereas HGFA/Fab40.DTrp yielded crystals
under 10% PEG 10,000, 100 mM HEPES (pH 7.5). For X-ray data collection,
the crystals were transferred to 14% PEG 10,000, 100 mM HEPES (pH 7.2),
20% glycerol and immersed in liquid nitrogen. X-ray data were collected at
100 K, either at beam line 9-2 at SSRL (HGFA/Fab40) or at ALS beam line
5.0.2 (HGFA/Fab40.DTrp and HGFA-KQLR/Fab40.DTrp) and reduced using
HKL2000 (Otwinowski and Minor, 1997). The structures were solved by molec-
ular replacement using PHASER (McCoy et al., 2005) and refined using CNX
(Accelrys) together with elements of the CCP4 suite (CCP4, 1994). Data reduc-
tion and model refinement statistics appear in Table 2. We prepared the
molecular graphics figures using PyMOL (http://www.pymol.org).
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a,b 0.050 (0.198) 0.094 (0.505) 0.143 (0.652)
I/sIb 15 (2.9) 14.0 (2.7) 15 (2.9)
Completeness (%)b 94.9 (86.9) 98.8 (98.3) 99.4 (97.3)
Redundancy 2.0 (1.9) 3.7 (3.6) 7.3 (7.4)
Refinement
Resolution (A˚) 20 – 2.35 20 – 2.90 20 – 2.70
No. of reflections 25746 32630 23158
Final Rc, Rfree 0.237, 0.291 0.216, 0.275 0.227, 0.278
No. of atoms
Protein 5046 9927 5138
Ligand 28 56 68
Water 168 153 133
B-factors (average)
Protein 65.27 68.92 35.86
Ligand 91.72 138.26 76.06
Water 58.37 39.42 29.65
Rmsd
Bond lengths (A˚) 0.008 0.008 0.007
Bond angles () 1.330 1.231 1.420
a Rsym = SkIj  j < I > k/Sj < I > j, where I is the intensity of a single obser-
vation and < I > is the average intensity for symmetry equivalent observa-
tions.
b In parentheses, for the highest-resolution shell.
c R =SjFo-Fcj/SjFoj, where Fo and Fc are observed and calculated struc-
ture factor amplitudes, respectively.Structure 17, 1614–1Sciences, of the U.S. Department of Energy under Contract No. DE-AC02-
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